Therapeutic Antibodies – News and Features

Researchers have built a synthetic receptor with broad potential to program cell activity, including immune response and neurological signaling.

UCLA researchers have developed a new approach to treating glioblastoma by combining genetic and functional profiling to predict tumor responses to therapies. The team showed promising results in tumor shrinkage.

RNA therapeutics promise rapid, personalized and flexible treatments against multiple diseases. In this article, we will explore whether RNA therapeutics can realize their full potential.

New study findings point to the potential of interleukin-13 antibodies — approved for use in humans — as a treatment to protect against bacterial pneumonia in patients with zinc deficiency.

A study reveals that triple-negative breast cancer cells prompt immune cells to form "molecular bridges," leading to immune suppression. An antibody treatment blocking these bridges shows promise in enhancing the immune response.

Georgia Tech researchers created AF2Complex, a deep-learning tool that predicts antibody interactions with proteins, enhancing immunotherapy development. The model accurately identified effective antibodies against Covid-19.

Caltech scientists have created a method to design antibodies that specifically recognize the cancer-causing mutant HER2 protein. This biologic could lead to effective therapies for patients with HER2 mutations.

The first randomized clinical trial on monoclonal antibodies' impact on long COVID found that the combination of amubarvimab and romlusevimab did not decrease long COVID symptoms.

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of lung cancer patients.

This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI efforts.